Literature DB >> 510119

Ambulatory diabetes management by a pulse of subcutaneous insulin delivered by a portable pump: preliminary report.

W J Riley, J H Silverstein, A L Rosenbloom.   

Abstract

Two teenage patients, who had severe psychosocial problems that complicated their diabetes management, were treated for one month (14-year-old girl) and two months (16-year-old boy) by frequent pulses of insulin injected subcutaneously by a portable, programmed pump. Additional pulses were manually adjusted by the patient before eating. Both patients experienced improved sense of well-being, marked reduction in urine volume and in glycosuria, and reduced glycemic excursions and average levels. The boy had accelerated linear growth and a decreas in HbA1 percentage. Despite marked clinical improvement, permitting return to school, the girl was impelled to interrupt pump administration after two weeks. Both patients continue to use the device voluntarily; a smaller unit, however, that doesn't have the conspicuous external controls, would likely be readily acceptable to most young patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 510119     DOI: 10.2337/diacare.2.3.272

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  3 in total

1.  Diabetes. II. Strict glycaemic control.

Authors:  D A Price
Journal:  Arch Dis Child       Date:  1984-09       Impact factor: 3.791

Review 2.  Continuous subcutaneous insulin infusion: a developing tool in diabetes research.

Authors:  J C Pickup; H Keen
Journal:  Diabetologia       Date:  1980-01       Impact factor: 10.122

3.  Use of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes mellitus: a systematic mapping review.

Authors:  Carolina Spinelli Alvarenga; Rebecca Ortiz La Banca; Rhyquelle Rhibna Neris; Valéria de Cássia Sparapani; Miguel Fuentealba-Torres; Denisse Cartagena-Ramos; Camila Lima Leal; Marcos Venicio Esper; Lucila Castanheira Nascimento
Journal:  BMC Endocr Disord       Date:  2022-02-19       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.